GlassScriptPhysician profile
Jerrelle M Copeland
NPI 1790784643
$4,384.41
in general payments reported to CMS, 2019-2025
35 companies · $1,152 in 2025
The $1,152 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $734 · 2020: $345 · 2021: $559 · 2022: $521 · 2023: $654 · 2024: $419 · 2025: $1,152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,194 · Entertainment: $17.07 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,194.31 |
| Entertainment | $17.07 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $810.76 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $477.63 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $420.46 | 2020-2025 | Ubrelvy, Vraylar |
| Amgen INC. | $311.73 | 2019-2025 | Evenity, Prolia |
| Intra-Sana Laboratories | $231.18 | 2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Boehringer Ingelheim Pharmaceuticals, INC. | $210.85 | 2019-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $210.85 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Abbott Laboratories | $194.17 | 2020-2025 | Freestyle Libre 2, Freestyle Libre 3, Proclaim |
| Inspire Medical Systems, INC. | $149.50 | 2024-2025 | Inspire |
| Lilly USA, LLC | $139.91 | 2019-2025 | Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $124.78 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $109.20 | 2019-2023 | |
| Astellas Pharma US INC | $99.44 | 2024-2025 | Veozah |
| Pfizer INC. | $95.98 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.74 | 2019-2024 | Xifaxan, Trulance |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $75.40 | 2023-2025 | Gemtesa |
| Takeda Pharmaceuticals U.S.A., INC. | $67.80 | 2019-2021 | |
| Exact Sciences Corporation | $60.47 | 2024-2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $58.45 | 2025 | Voquezna |
| Bardy Diagnostics, INC. | $57.57 | 2021 | |
| Eisai INC. | $50.24 | 2021-2025 | |
| Scilex Pharmaceuticals INC. | $48.23 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $45.86 | 2022-2025 | |
| Ultragenyx Pharmaceutical INC. | $44.97 | 2019-2020 | |
| Kyowa Kirin, INC. | $28.71 | 2024 | Crysvita |
| Otsuka America Pharmaceutical, INC. | $27.28 | 2023 | Abilify Mycite |
| Esperion Therapeutics, INC. | $23.05 | 2021 | |
| Globus Medical, INC. | $19.45 | 2025 | Senza |
| Kowa Pharmaceuticals America, INC. | $18.58 | 2023 | Livalo, Seglentis |
| Saluda Medical Americas, INC. | $18.38 | 2024 | Evoke |
| Optos, INC. | $17.07 | 2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Emergent Biosolutions INC. | $16.91 | 2019 | |
| Medtronic USA, INC. | $16.08 | 2019 | |
| Lucid Diagnostics INC. | $14.03 | 2022 | |
| Vivus LLC | $5.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerrelle Copeland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.